Clinical Trial Update: CTLA-4 and PD-1 Antibodies Expressing EGFR-CAR-T Cells for EGFR Positive Advanced Solid Tumor [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating EGFR-CAR-T cells engineered to express CTLA-4 and PD-1 antibodies for EGFR-positive advanced solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• CTLA-4 antibody
• EGFR-CAR-T cells expressing CTLA-4 and PD-1 antibodies
• PD-1 antibody (PD-1 inhibitor)

Snippet

Sponsor: Shanghai Cell Therapy Research Institute | Conditions: Advanced Solid Tumor | Phase 1, Phase 2 | Status: UNKNOWN